GEN1042 Safety Trial and Anti‑tumor Activity in Participants With Malignant Solid Tumors

Trial status:Recruitment Complete
Trial ID:
GCT1042-01
NCT ID:
NCT04083599
EudraCT ID:
2018-003716-47
EU Trial (CTIS) Number:
2023-508526-10
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genmab
Collaborator:
BioNTech SE
Recruitment Complete

Trial Details

The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.

Medical Condition
Solid Tumors
Lung Cancer
Colorectal Cancer
Skin Cancer
Head and Neck Cancer
Pancreatic Cancer
Study Drug
GEN1042
See more
Pembrolizumab
Cisplatin
Carboplatin
5-FU
Gemcitabine
Nab paclitaxel
Pemetrexed
Paclitaxel
Phase
Phase 1/Phase 2
Type
Interventional
Estimated Enrolment
350
Estimated Trial Date
Sep 2019 - Dec 2025

Trial Participant Requirements

Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Inclusion and Exclusion Criteria
Inclusion criteria

    Monotherapy - Dose Escalation and Dose Expansion Parts

  • Participants with non-CNS solid tumors that is metastatic or unresectable and for whom there is no available standard therapy.
  • Participants with a confirmed diagnosis of relapsed or refractory, advanced and/or metastatic melanoma, NSCLC, or CRC and for whom there is no available standard therapy

    • Combination Therapy - Dose Expansion Part

  • Participants with unresectable Stage III or Stage IV melanoma with no prior systemic anticancer therapy for unresectable or metastatic disease. Primary ocular or mucosal melanoma is excluded.
  • Participants with Stage IV metastatic or recurrent NSCLC with no prior systemic anticancer therapy, no actionable mutation.
  • Participants with recurrent or metastatic HNSCC with no prior systemic therapy administered in the recurrent or metastatic setting.
  • Participants with confirmed metastatic PDAC with no previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease.

    • General (all phases):

  • Must be age ≥ 18 years of age on the day of signing informed consent, or the legal age of consent in the jurisdiction in which the trial is taking place.
  • Measurable disease according to RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) 0-1
  • Normal or adequate liver, renal, cardiac and bone marrow function
Exclusion criteria

    Monotherapy - Dose Escalation and Dose Expansion Parts

  • Treatment with an anti-cancer agent (within 21 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1042 administration
  • Radiotherapy within 14 days prior to first GEN1042 administration
  • Toxicities from previous anti-cancer therapies that have not resolved

    • Combination Therapy - Dose Expansion Part

  • Has received prior systemic cytotoxic chemotherapy, biological therapy, OR major surgery within 3 weeks or at least 5 half-lives of the drug (whichever is shorter) of the first dose of trial treatment.
  • Radiotherapy within 14 days of start of trial treatment or received lung radiation therapy of \> 30 Gy within 6 months of the first dose of trial treatment.

    • General (all phases)

  • Participants has an active, known, or suspected autoimmune disease.
  • History of non-infectious pneumonitis that required steroids or currently has pneumonitis.
  • History of ≥ grade 3 allergic reactions to monoclonal antibody (mAb) therapy
  • Participants with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.

    • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial Locations

Location
Status
Location
Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States, 99508
Status
Location
Cancer & Blood Specialty Clinic
Los Alamitos, California, United States, 90720
Status
Location
Moores Cancer Center at the UC San Diego Health
San Diego, California, United States, 92037
Status
Location
Yale University Cancer Center
New Haven, Connecticut, United States, 06520
Status
Location
ChristianaCare
Newark, Delaware, United States, 19713
Status
Location
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States, 33140
Status
Go to page